June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Modified Allergen Challenge Induces Chronic Allergic Conjunctivitis that is alleviated by Treatment with Topical Steroid
Author Affiliations & Notes
  • Paulo Gomes
    Allergy, ORA, Andover, MA
  • Endri Angjeli
    Allergy, ORA, Andover, MA
  • Keith Lane
    Allergy, ORA, Andover, MA
  • Donna Welch
    Allergy, ORA, Andover, MA
  • Footnotes
    Commercial Relationships Paulo Gomes, Ora, Inc. (E); Endri Angjeli, Ora, Inc. (E); Keith Lane, Ora, Inc. (E); Donna Welch, Ora, inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2555. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paulo Gomes, Endri Angjeli, Keith Lane, Donna Welch; Modified Allergen Challenge Induces Chronic Allergic Conjunctivitis that is alleviated by Treatment with Topical Steroid. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2555.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

A significant portion of allergic conjunctivitis patients (approximately 30% of all ocular allergy sufferers) experience a more severe, late-phase allergic manifestation. This subpopulation of patients is not sufficiently treated with antihistamine therapy alone, and frequently develops a persistent chronic ocular surface inflammation due to repeated allergic events. The Conjunctival Allergen Challenge (CAC) is a proven model that effectively induces signs and symptoms of the acute allergic response. We have previously described variations of the CAC that can induce severe allergic responses suitable for evaluation of candidate anti-inflammatory compounds. Based on these efforts we have now developed a modified CAC model in which the timing and presentation of allergen has been designed simulate environmental allergen exposure. This model reproducibly creates signs and symptoms comparable to a late phase allergic response. The goal of the study described here was to validate this new model with a topical anti-inflammatory drug as a test treatment.


This Phase IV, IRB-approved, single-center, two-arm, placebo-controlled trial enrolled 9 volunteers 18 years of age or older with a history of allergic conjunctivitis. Subjects were challenged over a 3 day period using a unique conjunctival allergen challenge regimen designed to prolong the duration of allergic conjunctivitis signs and symptoms and create allergic inflammation. Qualified subjects were randomized to bilaterally receive either QID dosing with Prednisolone Phosphate 1.0% solution or vehicle for 7 days before repeating the challenge regimen. Itching, redness and chemosis were assessed at post treatment challenge sessions.


Clinically and statistically significant differences between treatment arms were demonstrated for both itching and for redness.


The modified CAC was able to generate a chronic allergic inflammatory condition that was responsive to steroid therapy. This model should be useful for evaluating potential therapies for the treatment of chronic ocular allergy.

Keywords: 421 anterior segment • 475 conjunctivitis • 479 cornea: clinical science  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.